Projects per year
Search results
-
Active
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers
Webber, K. (Primary Chief Investigator (PCI))
17/06/25 → 16/06/30
Project: Research
-
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Webber, K. (Primary Chief Investigator (PCI))
23/12/24 → 22/12/29
Project: Research
-
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
Webber, K. (Primary Chief Investigator (PCI))
21/10/24 → 20/10/29
Project: Research
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 Xport-EC-042 - A Phase 3, Randomized, placebo-controlled, double-blind, Multicenter trial of Selinexor in maintenance therapy after systemic therapy for patients with P53wild-type, advanced or recurrent endometrial carcinoma
Webber, K. (Primary Chief Investigator (PCI))
30/10/23 → 29/10/28
Project: Research
-
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
Frentzas, S. (Primary Chief Investigator (PCI)) & Webber, K. (Primary Chief Investigator (PCI))
21/03/22 → 15/03/27
Project: Research
-
PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Webber, K. (Primary Chief Investigator (PCI))
27/01/22 → 26/01/27
Project: Research
-
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Webber, K. (Primary Chief Investigator (PCI))
25/11/20 → 24/11/25
Project: Research
-
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Webber, K. (Primary Chief Investigator (PCI))
30/07/20 → 29/07/25
Project: Research
-
Finished
Real-time patient-reported outcomes measures (PROMs) and patient-reported experience measures (PREMS) in oncology: enhancing inclusivity and toward a new standard of care.
Segelov, E., Webber, K., White, M. & Grech, L.
1/07/22 → 31/10/23
Project: Research
-
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Webber, K. (Primary Chief Investigator (PCI))
15/11/19 → 14/11/24
Project: Research
-
PRECISE: A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated with Pamiparib in Subjects with Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion
Webber, K. (Primary Chief Investigator (PCI))
20/09/19 → 19/09/24
Project: Research